Home > RXi Pharmaceuticals Corp. RXII

Tag: RXi Pharmaceuticals Corp. RXII

MondayNov 03, 2008 5:19 am

RXi Pharmaceuticals Corp. (NASDAQ: RXII)

RXi Pharmaceuticals Corp. (NASDAQ: RXII), a discovery-stage biopharmaceutical company, is focused on developing and commercializing proprietary therapeutics, based on RNA interference (RNAi), to treat various human diseases. The company aims to leverage RNAi-based technologies across multiple therapeutic areas to initially treat neurological diseases, metabolic diseases and cancer. For further information, visit the Company's web site at www.rxipharma.com.

Continue Reading

MondayOct 06, 2008 9:09 am

RXi Pharmaceuticals Corp. (RXII) to Webcast Investor Event

RXi Pharmaceuticals Corp. (NASDAQ:RXII) is a discovery-stage biopharmaceutical company. The company is pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of human diseases. RXi Pharma intends to put their initial focus on the treatment of neurological and metabolic diseases and cancer. RNAi is a naturally-occurring mechanism for the regulation of gene expression that has the potential to be harnessed to selectively inhibit certain genes that lead to disease. Rxi Pharma was founded by world-leading researchers in the field of RNAi. Most notably, this includes Dr. Craig Mello, recipient of the 2006 Nobel…

Continue Reading

TuesdaySep 02, 2008 6:22 am

RedChip Featured Company: RXi Pharmaceuticals Corp. (RXII)

RXi Pharmaceuticals (RXII) is a biopharmaceutical company working towards the development and commercialization of proprietary therapies based upon RNA interference (RNAi). RNAi is considered to be a significant advancement in the field. In 2002, the journal Science selected RNAi as the “Breakthrough of the Year”. The discovery team, which included Dr. Craig Mello, one of the founders of RXi, was awarded the 2006 Nobel Prize in Medicine. It is believed that RNAi, which is a naturally occurring mechanism for the regulation of gene expression, can be used to selectively inhibit the activity of any human gene. RXi hopes to harness…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered

512.354.7000

Please read Disclaimers for FULL Compensation Disclosures and other disclaimers.

Copyright © .